Is that what Sustainable Earning stands for?: Novabay Pharmaceuticals Inc (NBY)

Novabay Pharmaceuticals Inc [NBY] stock is trading at $0.13, down -5.86%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NBY shares have gain 11.13% over the last week, with a monthly amount glided 71.17%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Novabay Pharmaceuticals Inc [AMEX: NBY] stock has seen the most recent analyst activity on September 18, 2019, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $1.10. Previously, H.C. Wainwright reaffirmed its Buy rating on July 06, 2018, and kept the price target unchanged to $4. On November 15, 2017, Laidlaw reiterated its Buy rating and revised its price target to $8 on the stock. ROTH Capital started tracking the stock assigning a Buy rating and suggested a price target of $5.50 on June 05, 2017. Laidlaw initiated its recommendation with a Buy and recommended $10 as its price target on March 27, 2017. Rodman & Renshaw started tracking with a Buy rating for this stock on February 06, 2017, and assigned it a price target of $6. In a note dated March 07, 2016, Maxim Group downgraded an Hold rating on this stock.

Novabay Pharmaceuticals Inc [NBY] stock has fluctuated between $0.06 and $1.28 over the past year. Novabay Pharmaceuticals Inc [AMEX: NBY] shares were valued at $0.13 at the most recent close of the market.

Analyzing the NBY fundamentals

Novabay Pharmaceuticals Inc [AMEX:NBY] reported sales of 14.23M for the trailing twelve months, which represents a drop of -15.78%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.77%, and Net Profit Margin reading is -0.92%. To continue investigating profitability, this company’s Return on Assets is posted at -2.45, Equity is -2.75 and Total Capital is -3.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 15.14.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1261 points at the first support level, and at 0.1205 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1424, and for the 2nd resistance point, it is at 0.1531.

Ratios To Look Out For

For context, Novabay Pharmaceuticals Inc’s Current Ratio is 0.92. Also, the Quick Ratio is 0.75, while the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 0.35.

Related Posts